You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國中藥(00570.HK)受委託生產透解祛瘟顆粒
格隆匯 02-10 06:30

格隆匯2月10日丨中國中藥(00570.HK)公佈,廣州市第八人民醫院的醫院中藥製劑透解祛瘟顆粒通過廣東省醫療機構傳統中藥製劑應急審批備案,並委託公司控股子公司廣東一方製藥有限公司進行生產配製。

2月8日,省藥監局、廣東省衞生健康委員會、廣東省中醫藥局聯合發佈《關於透解祛瘟顆粒臨牀使用有關規定的通知》,允許廣東省新型冠狀病毒感染的肺炎定點救治醫院,根據臨牀需要直接調劑使用透解祛瘟顆粒,無需向省藥監局提出調劑申請;非廣東省定點醫院申請調劑使用透解祛瘟顆粒的,由省藥監局予以優先審批。獲調劑的醫療機構可直接向廣東一方申請提供配送。

公告顯示,廣東一方憑藉之前在中藥配方顆粒研究過程中的經驗和數據積累,快速完成了透解祛瘟顆粒備案產品的生產、檢驗和申報,並獲得了醫療機構製劑委託配製批件,目前已積極組織生產配送。

據悉,集團將繼續密切關注疫情發展情況,全力保障疫情防控藥品的供應,積極承擔醫藥企業社會責任,為抗擊疫情,為人民羣眾生命安全和身體健康貢獻力量。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account